Related Experiment Video
Updated: Jul 14, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
Published on: May 11, 2022
Linezolid-induced posterior reversible leukoencephalopathy syndrome
Simon Nagel1, Martin Köhrmann, Hagen B Huttner
1Department of Neurology, University of Heidelberg, Heidelberg, Germany. simon.nagel@med.uni-heidleberg.de
Objective:
To describe a 71-year-old woman who developed clinical and neuroradiological features of posterior reversible leukoencephalopathy syndrome with a compromised blood-brain barrier after 5 days of intravenous linezolid therapy for an infected hip prosthesis.
Design:
Case report.
Setting:
Academic research.
Main Outcome Measures:
Posterior reversible leukoencephalopathy syndrome was documented using serial cranial magnetic resonance imaging, and the blood-brain barrier disturbance was demonstrated by contrast enhancement of a lesion and by cerebrospinal fluid analysis.
Results:
Other causes of posterior reversible leukoencephalopathy syndrome, such as renal failure, severe hypertension, inflammatory syndromes, and infectious diseases of the central nervous system, were excluded during hospitalization. After discontinuation of linezolid therapy, the patient's condition improved rapidly.
Conclusion:
To our knowledge, this is the first report of likely linezolid-induced posterior reversible leukoencephalopathy syndrome with an altered blood-brain barrier after short-term intravenous therapy.
Related Concept Videos
Encephalitis ll: Pathophysiology
Encephalitis l: Introduction
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Rabies
Hepatic Encephalopathy
Antiprotozoal Agents